AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NeOnc Technologies Enhances NEO100 Potency with AI-Driven Ultrasound Findings.
ByAinvest
Friday, Dec 5, 2025 5:05 pm ET1min read
NeOnc Technologies has announced preclinical findings from a research collaboration at the University of Southern California. The study shows that ultrasound enhances the potency of NEO100, a brain-penetrant therapeutic for CNS cancers, driving strong antitumor effects across multiple primary and metastatic brain tumor types. The findings were published on bioRxiv and utilize AI-driven, 3D-bioprinted New Approach Methodology (NAM).
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet